Revance Therapeutics Inc (RVNC)

[DewDiligence]

The Morgan Stanley analyst is blatantly dishonest. In the excerpt you posted, the analyst says Daxxify’s probability of success (”PoS”) in CD was raised from 80% to 100% following FDA approval in this indication. However, prior to FDA approval this analyst had modeled the probably of success in CD at 70% (not 80%), a figure that I ridiculed in #msg-170173399.